Check out this interview with professor Matthew Johnson at Johns Hopkins University. He’s an expert on psychedelics, drugs, and addiction.
Read moreMore on Psychedelics
Psychedelics continue to show promising treatment for depression, anxiety and PTSD.
Read moreNeural Plasticity
Psychedelic drugs may have mind-altering powers in the physical sense, too. A study has found psychedelics, specifically DOI, DMT, and LSD, can change brain cells in rats and flies, making neurons more likely to branch out and connect with one another. The work supports the theory that psychedelics could help to fight depression, anxiety, addiction, and post-traumatic stress disorder.
Read moreResearch Update on Psychedelics
This sums up the new wave of research on psychedelics.
Read moreKeep Talking!
Why talking about our problems helps, and how to do it.
Read morePsilocybin Therapy for Smoking Addiction
A pilot study saw that 80% of participants quit smoking after one dose of psilocybin and research on 51 cancer patients showed the drug decreased anxiety and depression in 80% of those tested.
Read morePsychedelic Research
Here’s an interview with a psychiatry resident on psychedelic research, where it’s going, where it’s been.
Read moreMore on Psychedelic Research
Johns Hopkins center is bringing renewed rigor to the investigation of the drugs’ therapeutic uses. Here’s an update.
Read moreKetamine for Depression
Here’s a look at the current research on ketamine for depression and mood disorders.
Read moreThe Future of Psychedelics
Here’s a look at what the future of psychedelic science holds.
Read moreResearch on 5-MeO-DMT
In addition to reducing symptoms of depression, the psychedelic drug 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) appears to cause changes in inflammatory biomarkers.
Read more